# ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

> **NCT06816992** · PHASE1 · RECRUITING · sponsor: **ORIC Pharmaceuticals** · enrollment: 76 (estimated)

## Conditions studied

- Solid Tumors
- EGFR Exon 20 Insertion Mutations
- NSCLC
- EGFR-mutated NSCLC

## Interventions

- **DRUG:** ORIC-114 Dose 1 + amivantamab
- **DRUG:** ORIC-114 Dose 2 + amivantamab
- **DRUG:** ORIC-114 Dose 3 + amivantamab

## Key facts

- **NCT ID:** NCT06816992
- **Lead sponsor:** ORIC Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816992, "ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06816992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*